Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Xyloside xylosyltransferase 1 (XXYLT1) is a type II membrane glycosyltransferase of the glycosyltransferase family 8, primarily residing in the endoplasmic reticulum. It transfers a xylose residue from UDP-xylose to a pre-existing xylose on the glucose-xylose (Xyl-Glc) disaccharide of epidermal growth factor (EGF)-like repeats, notably on the Notch receptor extracellular domain. This post-translational modification is part of the canonical glycosylation of Notch receptors and modulates their signaling function. Mutations or dysregulation of XXYLT1 can influence Notch-dependent cellular processes, with emerging evidence supporting a role in some cancers, particularly where Notch signaling is implicated. The detailed mechanism of catalysis involves direct nucleophilic attack from the acceptor xylose, consistent with an S~N~i-like retaining glycosyltransferase mechanism[1].
Catalytic transfer of xylose in an α1–3 linkage to an existing xylose on EGF-like repeats using a retaining glycosyltransferase mechanism; mechanistically, likely uses an S~N~i-like internal return reaction retaining the configuration at the anomeric carbon[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Xyloside xylosyltransferase 1 (XXYLT1).